Indicated for the treatment of Parkinson's disease.
Orphenadrine binds and inhibits both histamine H1 receptors and NMDA receptors. It restores the motor disturbances induced by neuroleptics, in particular the hyperkinesia. The dopamine deficiency in the striatum increases the stimulating effects of the cholinergic system. This stimulation is counteracted by the anticholinergic effect of orphenadrine. It may have a relaxing effect on skeletal muscle spasms and it has a mood elevating effect.
Oral, mouse LD<sub>50</sub> = 100 mg/kg; oral, rat LD<sub>50</sub> = 255 mg/kg
Orphenadrine is almost completely absorbed in the gastrointestinal tract.
13-20 hours